Revolutionising Cardiometabolic Health: Innovating, Transforming and Progressing Care
Alice Cheng; Ania Jastreboff; Anna Secher; Antje Körner; Arya M. Sharma; Athena Philis-Tsimikas; Carel le Roux; Christoph Wanner; Harald Sourij; John Buse; Laurent Castera; Linong Ji; Matthias Blüher; Melanie Davies ; Michele Senni; Mikael Rydén; Subodh Verma; W. Timothy Garvey
MATERIALS AVAILABLE
Summary Slides
Summary Slides
Summary Slides
Summary Slides
Summary Slides
Full Recording
Full Recording
Full Recording
Full Recording
Full Recording
Infographic
Infographic
Infographic
Infographic
Infographic
Tuesday, 16 September 2025
10:15 - 10:30
CEST
ORAL PRESENTATION
Oral semaglutide and cardiovascular outcomes by baseline A1c and BMI in people with type 2 diabetes in the SOUL trial
Silvio E. Inzucchi1; Rohana Abdul Ghani2; John Deanfield3; Mads D. M. Engelmann4; G. Kees Hovingh4; Ole K. Jeppesen4; Monika Kellerer5; Kabirdev Mandavya6; Johannes F. Mann7; Nikolaus Marx8; Chantal Mathieu9; Darren K. McGuire10; Viswanathan Mohan11; Sharon L. Mulvagh12; Rodica Pop-Busui13; Neil R. Poulter14; Maria Sejersten Ripa4; Gabriela Roman15; Róbinson Sánchez García16; Michael Shechter17; John B. Buse18; on behalf of the SOUL Study Group
MATERIALS AVAILABLE
Slide
12:00 - 13:00
CEST
LBA 43
SHORT ORAL PRESENTATION
Efficacy and safety of cagrilintide 2.4 mg in adults with overweight/obesity: Data from REDEFINE 1
W. Timothy Garvey1; Lei Liu2; John Rømer2; Kirsi H. Pietiläinen3; Ketil Biering Tvermosegaard2; David C.W. Lau4
MATERIALS AVAILABLE
Slide
Poster
12:00 - 13:00
CEST
873
SHORT ORAL PRESENTATION
Improved treatment satisfaction with once-weekly IcoSema vs daily basal-bolus therapy in adults with type 2 diabetes inadequately controlled on daily basal insulin (COMBINE 3)
Paolo Fiorina1; Malik Benamar2; Sin Gon Kim3; Raluca Maltesen4; Siri Vinther2; Liming Chen5
MATERIALS AVAILABLE
Slide
12:00 - 13:00
CEST
869
SHORT ORAL PRESENTATION
Efficacy and hypoglycaemia outcomes with once-weekly IcoSema vs comparators in type 2 diabetes according to pre-trial sodium-glucose cotransporter-2 inhibitor use: a post hoc analysis of COMBINE 1–3
Linong Ji1; Jonas Dahl Andersen2; Sofie Bech Andersen3; Laura Pletsch-Borba3; Viswanathan Mohan4; Daisuke Yabe5
MATERIALS AVAILABLE
Slide
12:00 - 13:00
CEST
872
SHORT ORAL PRESENTATION
Gastrointestinal adverse events with once-weekly IcoSema: a post hoc analysis of COMBINE 1–3
André Vianna1; Jonas D Andersen2; Liming Chen3; Paolo Fiorina4; Thaís M P Rocha5; Siri Vinther5; Liana K Billings6
MATERIALS AVAILABLE
Slide
12:00 - 13:00
CEST
870
SHORT ORAL PRESENTATION
Continuous glucose monitoring-based outcomes in adults with type 2 diabetes receiving IcoSema vs comparators: post hoc analysis of COMBINE 1 and 3
Concetta Irace1; Vanja Cejvanovic2; Jonas H Larsen3; Thaís MP Rocha2; Yasuo Terauchi4; Chantal Mathieu5
MATERIALS AVAILABLE
Slide
12:00 - 13:00
CEST
871
SHORT ORAL PRESENTATION
Continuous glucose monitoring-derived model-based postprandial glucose with IcoSema vs other insulin regimens: a post hoc analysis of COMBINE 1 and 3
Christophe De Block1; Malik Benamar2; Ariel Fu2; Raluca Maltesen3; Francesco Giorgino4
MATERIALS AVAILABLE
Slide
12:00 - 13:00
CEST
LBA 45
ORAL PRESENTATION
Impact of food noise after initiating semaglutide treatment: results from a US survey (INFORM)
Assessing thyroid cancer risk: GLP-1 RA shows short to intermediate-term safety
Vanita Aroda1,2; Tina Vilsbøll3,4; Sune Dandanell5; Jens-Peter David5; Ceyda T P Kristiansen5; Fiona Roberts5; Michael Stellfeld5; Laszlo Hegedus6;
MATERIALS AVAILABLE
Slide
13:15 - 14:15
CEST
555
ORAL PRESENTATION
Impact of semaglutide on liver-related responses in people with metabolic dysfunction-associated steatohepatitis (MASH) with/without type 2 diabetes (T2D): Post hoc analysis of the ESSENCE trial
Elisabeth Bugianesi1; Teresa Arias-Loste2; Laurent Castera3; Nathalie Marcela Eklöf4; Won Kim5; Niels Krarup4; Bernhard Ludvik6; Philip Newsome7; Vlad Ratziu8; Mary Rinella9; Arun Sanyal10; Anca Trifan11; Thea Vestergaard4; Michael Roden12; ESSENCE study group
MATERIALS AVAILABLE
Slide
14:45 - 16:15
CEST
63
ORAL PRESENTATION
Amycretin, a novel, unimolecular glucagon-like peptide-1 and amylin receptor agonist: Results of a phase 1b/2a clinical trial
Kirsten Dahl1; Kasper Adelborg2; Sohan Dey3; Ruben Duque do Vale2; Cassandra Key4; Søren Toubro2; Ania M. Jastreboff5
MATERIALS AVAILABLE
Slide
Poster
Video
16:15 - 16:45
CEST
Symposium
Proactive care: early detection and interdisciplinary approaches for managing chronic kidney disease and peripheral artery disease in people with T2D
Ildiko Lingvay; David Cherney; Marc P. Bonaca
MATERIALS AVAILABLE
Full Recording
18:00 - 19:30
CEST
Symposium
Person-centred care in obesity management: connecting with your patients
Carel le Roux; Paolo Sbraccia; Steven Kahn; Ildiko Lingvay; Domenica Rubino
MATERIALS AVAILABLE
Full Recording
Infographic
Wednesday, 17 September 2025
2<\/sup> and type 2 diabetes\n`,
`Vienna, Austria`
)">
09:45 - 11:15
CEST
73
ORAL PRESENTATION
REDEFINE 2: A randomised trial of combined semaglutide 2.4 mg and cagrilintide 2.4 mg for the treatment of adults with BMI ≥27 kg/m2 and type 2 diabetes
Melanie J Davies1; Harpreet S Bajaj2; Christa Broholm3; Astrid Eliasen3; W Timothy Garvey4; Carel W le Roux5; Ildiko Lingvay6; Christian Bøge Lyndgaard3; Julio Rosenstock7; Lisa von Huth Smith3; Sue D Pedersen8
MATERIALS AVAILABLE
Coming soon
09:45 - 11:15
CEST
76
ORAL PRESENTATION
Safety of semaglutide among people treated with dialysis: a pooled analysis of SUSTAIN-6, SELECT, FLOW, and SOUL
Klara R. Klein1; Anna Menacher2; Katherine R. Tuttle3; Andrea Storås2; Margit R. Andersen2; Manuel Mayrdorfer2; Ildiko Lingvay4
MATERIALS AVAILABLE
Slide
13:00 - 14:00
CEST
895
SHORT ORAL PRESENTATION
Efficacy and hypoglycaemia outcomes with once-weekly insulin icodec vs once-daily basal insulin in type 2 diabetes by diabetes duration: ONWARDS 1–5
Alice YY Cheng1; Gayathri Anil2; Luis Canani3; Jonas K Lindeløv4; Siri Vinther4; Chantal Mathieu5
MATERIALS AVAILABLE
Slide
13:00 - 14:00
CEST
710
SHORT ORAL PRESENTATION
Effect of semaglutide on the initiation of additional glucose-lowering therapy: An analysis of the SELECT trial
Steven E Kahn1; Ole Kleist Jeppesen2; A Michael Lincoff3; Ildiko Lingvay4; Jorge Plutzky5; Anders Rasmussen Rinnov2; Donna H Ryan6; Scott S Emerson7
MATERIALS AVAILABLE
Slide
14:30 - 14:45
CEST
ORAL PRESENTATION
Effects of oral semaglutide on hospitalisation rates in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease: SOUL trial results
John B. Buse1; Nikolaus Marx2; Sharon L. Mulvagh3; John Deanfield4; Silvio E. Inzucchi5; Rodica Pop-Busui6; Johannes F. E. Mann7; Scott Emerson8; Neil R. Poulter9; Mads D.M. Engelmann10; G. Kees Hovingh10; Rohana Abdul Ghani11; Aslam Amod12; Stephen C. Bain13; Pardeep S. Jhund14; Aytekin Oguz15; Michael Shechter16; Alex Videmark10; Derrick Musinga17; Amin Ouahid Hessissen10; Marie Reeberg Sass10; Darren K. McGuire18; on behalf of the SOUL Study Group
MATERIALS AVAILABLE
Slide
2<\/sup> and type 2 diabetes (T2D) within the blinded continuous glucose monitoring (CGM) subgroup in REDEFINE 2\n`,
`Vienna, Austria`
)">
14:30 - 16:00
CEST
LBA 13
ORAL PRESENTATION
CagriSema improves glycaemic outcomes across weight loss categories in adults with BMI ≥27 kg/m2 and type 2 diabetes (T2D) within the blinded continuous glucose monitoring (CGM) subgroup in REDEFINE 2
Richard Pratley1; Harpreet S. Bajaj2; Christa Broholm3; Maria M Byrne4; Mikkel Hovden Christensen3; Astrid Eliasen3; Josefine Nadia Kraft3; Ildiko Lingvay5; Sean Wharton6; Melanie J. Davies2
MATERIALS AVAILABLE
Slide
14:30 - 16:00
CEST
LBA 15
ORAL PRESENTATION
Pharmacokinetics, safety and tolerability of amycretin in people with renal impairment
Sine Pfeiffer Haugaard1; Tobias Karlsson1; Victoria Kegel-Hübner2; Lykke Ida Kaas Oldenburg1; Mahera Parwez3; Christoffer Wiingaard1; Anne Flint1
MATERIALS AVAILABLE
Slide
17:45 - 19:15
CEST
Symposium
The evolving role of GLP-1RAs for holistic cardiovascular, kidney, liver and metabolic care
Steven Kahn; John Wilding; Paola Fioretto; Eric Lawitz; Subodh Verma
MATERIALS AVAILABLE
Full Recording
Infographic
Thursday, 18 September 2025
10:45 - 12:15
CEST
147
ORAL PRESENTATION
Effect of semaglutide on body composition and proximal muscle strength: The STEP UP trial
Jøran Hjelmesæth1; Suhas Bhat2; W Timothy Garvey3; Kristoffer Jensen Kolnes4; Ildiko Lingvay5; Niklas Kahr Rasmussen4; Julio Rosenstock6; Sean Wharton7
MATERIALS AVAILABLE
Slide
Video
10:45 - 12:15
CEST
145
ORAL PRESENTATION
Effect of semaglutide 7.2 mg on anthropometric measures of obesity: The STEP UP trial
Sean Wharton1; Jøran Hjelmesæth2; Ildiko Lingvay3; Hanna Angelene K M4; Maria De Los Angeles Quiroga Pelaez5; Niklas Kahr Rasmussen5; Julio Rosenstock6; W Timothy Garvey7
MATERIALS AVAILABLE
Slide
Video
10:45 - 12:15
CEST
LBA 22
ORAL PRESENTATION
Incidence of non-arteritic ischaemic optic neuropathy (NAION) across completed phase 2, 3 and 4 trials evaluating the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide
Tina Vilsbøll1,2; Dikshit A3; Lloyd Paul Aiello4; Cecilia Rönnbäck5; Michael Stellfeld5; Michael Larsen6;
MATERIALS AVAILABLE
Slide
10:45 - 12:15
CEST
148
ORAL PRESENTATION
Impact of once-weekly semaglutide on cardiovascular events in adults with overweight or obesity in a real-world Danish population
João Fernandes1; Timothy Arnaut1; Natalie Clausen2; Lise Meinicke Hagelund2; Mathilde Kany3; Michael Maengd4
MATERIALS AVAILABLE
Slide
10:45 - 12:15
CEST
146
ORAL PRESENTATION
Control of eating with semaglutide 7.2 mg in adults with obesity: The STEP UP trial
Sean Wharton1; Suhas Bhat2; Michelle Dalton3; Jøran Hjelmesæth4; Ildiko Lingvay5; Maria De Los Angeles Quiroga Pelaez6; Niklas Kahr Rasmussen6; Julio Rosenstock7; Jena S Tronieri8; W Timothy Garvey9
MATERIALS AVAILABLE
Slide
Video
10:45 - 12:15
CEST
LBA OP 04
ORAL PRESENTATION
Comparative Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide on Cardiovascular Outcomes in US Medicare Beneficiaries With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
Semaglutide and risk reduction of major adverse limb events in diabetes: A pooled analysis of 13,975 participants from the SOUL, FLOW and STRIDE randomised trials
Subodh Verma1; Marc P. Bonaca2; Joakim Nordanstig3; John B. Buse4; Matthew A. Cavender4; Kenneth W. Mahaffey5; Richard Pratley6; Peter Rossing7; Alex Videmark8; Andrei-Mircea Catarig8; Søren Rasmussen8; Florian M. M. Baeres8; Mads D. M. Engelmann8; Darren K. McGuire9
MATERIALS AVAILABLE
Slide
12:15 - 12:45
CEST
Symposium
A new era of cardiometabolic care: advancing holistic treatment ambitions with amylin
Alice Cheng; Arya M. Sharma
MATERIALS AVAILABLE
Full Recording
15:30 - 17:00
CEST
190
ORAL PRESENTATION
REDEFINE 1: A randomised study of combined semaglutide 2.4 mg and cagrilintide 2.4 mg for the treatment of overweight or obesity in adults
W. Timothy Garvey1; Matthias Blüher2; Cynthia Karenina Osorto Contreras3; Melanie J. Davies4; Eva Winning Lehmann3; Kirsi H. Pietiläinen5; Domenica Rubino6; Paolo Sbraccia7; Lisa von Huth Smith3; Thomas Wadden8; Niels Zeuthen3; John Wilding9
MATERIALS AVAILABLE
Slide
15:30 - 17:00
CEST
181
ORAL PRESENTATION
Efficacy and hypoglycaemia outcomes with once-weekly insulin icodec vs once-daily basal insulin in type 2 diabetes by baseline HbA1c: ONWARDS 1–5
Alice YY Cheng1; Gayathri Anil2; Luis Canani3; Jonas K Lindeløv4; Siri Vinther4; Chantal Mathieu5
MATERIALS AVAILABLE
Slide
15:30 - 15:45
CEST
188
ORAL PRESENTATION
The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats
Rune E Kuhre1; Borja Ballarín-González2; Christian L Brand1; Tine Glendorf1; Kim Grimstrup Madsen1; Karina R Hjøllund1; Wouter FJ Hogendorf3; David H Ipsen1; Sofia Lundh1; Thomas Kruse3; Signe B Petersen1; Anna Secher1; Andreas Vegge4; Kirsten Raun1
MATERIALS AVAILABLE
Slide
17:00 - 17:30
CEST
Symposium
From at-risk to recognition: improving detection of MASH